Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Newer radiation technique may spare bladder and bowel in endometrial cancer patients

NCT ID NCT01164150

Symptom relief Sponsor: Cancer Trials Ireland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This trial compared two ways of giving pelvic radiotherapy after surgery for endometrial cancer: standard 3D planning versus a newer technique called IMRT. The goal was to see if IMRT could reduce side effects like bladder and bowel problems. The study enrolled 92 participants but was stopped early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiation therapy (IMRT vs 3D planned)
What this could lead to
If successful, this could show that IMRT reduces short-term bowel and bladder side effects compared to standard 3D radiotherapy for endometrial cancer patients.
What could go wrong
This is a small, early-phase trial that was terminated early, so results may be limited. It does not test survival or cancer control, only side effect reduction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

92 people

The number who actually took part.

Started

Mar 2010

Finished

Mar 2020

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing adjuvant pelvic radiotherapy for histologically confirmed endometrial adenocarcinoma / serous carcinoma / papillary serous carcinoma / mixed histology (adenocarcinoma and serous) and following AJCC 2009 grade/stage: * Grade 2: stage IB (LVSI +/or \>60yrs) * Grade 3: stage IA and IB * Grade 1-3: Stage II and IIIA, IIIB and IIIC1 * Surgery consisting of total hysterectomy, +/- bilateral salpingo-oophorectomy, +/- lymph node sampling * Staging with imaging of pelvis and abdomen (either MRI or CT) * ECOG PS 0-2 * Age ≥ 18 years * Provision of written informed consent in line with ICH-GCP guidelines Exclusion Criteria: * Previous radiotherapy to the pelvic region * Patients in whom concurrent chemotherapy in planned * Patients with macroscopic disease in situ * History of inflammatory bowel disease * Previous hip replacement * Previous bowel surgery (excluding appendectomy) * Patients with other syndromes/conditions associated with increased radiosensitivity * The patient has or had other co-existing malignancies within the past 5 years other than non-melanoma skin cancer * Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study or if it is felt by the research / medical team that the patient may not be able to comply with the protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrial mixed adenocarcinoma endometrial serous adenocarcinoma endometrium adenocarcinoma endometrium neoplasm radiation injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial cancer Gastrointestinal complications Radiation toxicity Urinary complications

Contacts and locations

Locations

  • Mid-Western Radiation Oncology Centre

    Limerick, Ireland

  • St Luke's Centre for Radiation Oncology at Beaumont Hospital

    Dublin, Ireland

  • St Luke's Centre for Radiation Oncology at St James Hospital

    Dublin, Ireland

  • St Luke's Centre for Radiation Oncology at St Lukes Hospital

    Dublin, Ireland

  • St Luke's Radiation Oncology Network (SLRON) Centres

    Dublin, 6, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.